PMID- 36645145
OWN - NLM
STAT- MEDLINE
DCOM- 20230227
LR  - 20230509
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 57
IP  - 6
DP  - 2023 Mar
TI  - Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients 
      with ulcerative colitis.
PG  - 610-619
LID - 10.1111/apt.17386 [doi]
AB  - BACKGROUND: Evidence on real-world outcomes of ustekinumab for ulcerative colitis 
      (UC) patients is needed. AIMS: To summarise evidence on the real-world outcomes 
      of ustekinumab for UC and conduct a meta-analysis of effectiveness and safety 
      data. METHODS: A systematic search was conducted through September 2022 in 
      electronic databases for observational studies evaluating ustekinumab for UC. A 
      random-effects meta-analysis model was used to calculate the pooled effect sizes 
      (percentages or incidence rates [IRs]) of effectiveness and safety outcomes. 
      RESULTS: In all, 19 studies were included with 3786 patients. More than 92% of 
      patients were previously treated with any biologic, 61.1% with both anti-TNF and 
      vedolizumab and 16.4% with any biologic and tofacitinib. Clinical remission was 
      achieved in 45.4% at week 8 (95% CI: 30.1%-60.6%), 43.8% (38.4%-49.2%) at weeks 
      12-16, 44.6% (35.9%-53.3%) at month 6, and 50.6% (36.3%-64.8%) at month 12. 
      Response was achieved in 61.2%, 59.4%, 65.2% and 76.8% at weeks 8, 12-16, month 6 
      and 12, respectively. CS-free remission was achieved in 18.7%, 36.8%, 34.5% and 
      39% at weeks 8, 12-16, month 6 and 12, respectively. Overall, 58.2% of patients 
      had endoscopic improvement at month 12. Almost 30% of the patients needed dose 
      escalation, which was effective in 40% of these patients. The IRs of colectomy, 
      adverse events (AEs), serious AEs and serious infections were 4.8, 7.9, 0.8 and 
      0.3 per 100 patient-years, respectively. CONCLUSIONS: This meta-analysis confirms 
      the effectiveness and safety of ustekinumab in a highly treatment-refractory 
      population of UC patients.
CI  - (c) 2023 John Wiley & Sons Ltd.
FAU - Taxonera, Carlos
AU  - Taxonera C
AUID- ORCID: 0000-0001-9166-7350
AD  - Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinico 
      San Carlos and Instituto de Investigacion del Hospital Clinico San Carlos 
      [IdISSC], Madrid, Spain.
FAU - Olivares, David
AU  - Olivares D
AUID- ORCID: 0000-0003-3506-7355
AD  - Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinico 
      San Carlos and Instituto de Investigacion del Hospital Clinico San Carlos 
      [IdISSC], Madrid, Spain.
FAU - Lopez-Garcia, Olga N
AU  - Lopez-Garcia ON
AUID- ORCID: 0000-0002-7397-0177
AD  - Gastroenterology Department, Hospital Clinico San Carlos, Madrid, Spain.
FAU - Alba, Cristina
AU  - Alba C
AD  - Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinico 
      San Carlos and Instituto de Investigacion del Hospital Clinico San Carlos 
      [IdISSC], Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20230116
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - FU77B4U5Z0 (Ustekinumab)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 0 (Biological Products)
SB  - IM
MH  - Humans
MH  - *Colitis, Ulcerative/drug therapy
MH  - Ustekinumab/therapeutic use
MH  - Tumor Necrosis Factor Inhibitors/therapeutic use
MH  - Colectomy
MH  - *Biological Products/therapeutic use
MH  - Treatment Outcome
MH  - Remission Induction
OTO - NOTNLM
OT  - effectiveness
OT  - meta-analysis
OT  - real world
OT  - safety
OT  - systematic review
OT  - ulcerative colitis
OT  - ustekinumab
EDAT- 2023/01/17 06:00
MHDA- 2023/03/03 06:00
CRDT- 2023/01/16 07:03
PHST- 2022/11/22 00:00 [revised]
PHST- 2022/10/24 00:00 [received]
PHST- 2022/12/29 00:00 [accepted]
PHST- 2023/01/17 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2023/01/16 07:03 [entrez]
AID - 10.1111/apt.17386 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2023 Mar;57(6):610-619. doi: 10.1111/apt.17386. Epub 2023 
      Jan 16.